BETAAccess all features while we're in beta! Some features may become paid later.Send feedback →
vpside

SLS

SELLAS Life Sciences Group, Inc.
Nasdaq · Pharmaceutical preparations (SIC 2834) · FY ends 31 Dec

Revenue, quarterly

$0
$6M$4M$2M$0
Q1 ’19Q2 ’20Q3 ’21Q3 ’22Q4 ’23
Company filings · 10-K filed 28 Mar 2024 · Q4 = FY − 9Mvpside.com

Gross margin, trailing twelve months

90.0%−7.4 pp year on year
100%95%90%
Q1 ’18Q2 ’19Q3 ’20Q3 ’21Q4 ’22
Company filings · 10-K filed 28 Mar 2024 · TTM = last four quartersvpside.com

Cash and cash equivalents, quarter-end

$138M+446.9% year on year
$150M$100M$50M$0
Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26
Company filings · 10-Q filed 11 Aug 2026 · balance sheet, period-endvpside.com

Free cash flow, trailing twelve months

−$12M
$20M$0−$20M−$40M−$60M
Q1 ’12Q2 ’13Q3 ’14Q3 ’15Q4 ’16
Company filings · 10-K filed 13 Apr 2018 · TTM = last four quartersvpside.com
Chart 05 is empty
Chart 06 is empty